PhaseBio Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. PhaseBio Pharmaceuticals's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 97% to $10,831. The net income raised on -$131,071 and profit margin reached -1210%. Total operating expenses were $118,193.
Profit Margin
| 2016 | 0 | -9.22M | |
|---|---|---|---|
| 2017 | 0 | -10.24M | |
| 2018 | 668K | -23.84M | -3569.76% |
| 2019 | 2.36M | -39.24M | -1662.3% |
| 2020 | 320K | -98.56M | -30801.56% |
| 2021 | 10.83K | -131.07K | -1210.15% |
PHAS Income Statement (2016 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
Revenue | ||||||
Revenue | 10.83K | 320K | 2.36M | 668K | 0 | 0 |
Cost of revenue | 0 | 319.68K | 0 | 0 | 0 | 0 |
Gross profit | 10.83K | 320 | 2.36M | 668K | 0 | 0 |
Operating exp. | ||||||
Research and development | 102.10K | 72.08M | 30.91M | 15.45M | 6.21M | 7.37M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 118.19K | 85.17M | 42.09M | 20.31M | 8.53M | 9.50M |
Operating income | -130.41K | -84.85M | -39.73M | -19.64M | -8.53M | -9.50M |
Other income (expenses), net | 947 | -13.70M | 489K | -4.20M | -1.70M | 281K |
Income before tax | -129.47K | -98.56M | -39.24M | -23.84M | -10.24M | -9.22M |
Income tax expense | 1.6K | -12.26M | 1.56M | -278K | 1.01M | 281K |
Net income | -131.07K | -98.56M | -39.24M | -23.84M | -10.24M | -9.22M |
Earnings per share | ||||||
Basic EPS | -0.00 | -3.39 | -1.43 | -4.49 | -0.91 | -0.74 |
Diluted EPS | -0.00 | -3.39 | -1.43 | -4.49 | -0.91 | -0.74 |
| Data source | Data source | Data source | Data source |